The results of the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER; number. Editorial from The New England Journal of Medicine — JUPITER Clinical Directions — Polling Results. Authors & Reviewers · Submit a Manuscript · Subscribers · Institutions · Media · Advertisers · Agents · Permissions · Reprints · NEJM Career.

Author: Faera Tarn
Country: Uganda
Language: English (Spanish)
Genre: Science
Published (Last): 24 February 2008
Pages: 279
PDF File Size: 14.39 Mb
ePub File Size: 10.55 Mb
ISBN: 147-3-95603-880-7
Downloads: 59975
Price: Free* [*Free Regsitration Required]
Uploader: Vudorn

An I ntervention T rial E valuating R osuvastatin nej, was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels. JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease. The trial focused on patients with normal low-density lipoprotein LDL cholesterol levels but increased levels of high-sensitivity C-reactive protein hs-CRP.

Because half of all vascular events occur in patients with normal or low levels of LDL cholesterol, JUPITER jupiyer designed to determine whether hs-CRP testing could identify these patients, and whether statin therapy could prevent cardiovascular events among them.

The trial analyzed 17, patients without evidence of heart disease but with high CRP levels. Inresults presented at the American Heart Association meeting and published in the New England Journal of Medicine found that patients with low-to-normal LDL cholesterol receiving rosuvastatin had a lower rate of major cardiovascular neejm.


Compared to patients taking a placebopatients jupite rosuvastatin had reductions in LDL and CRP levels, and a reduction of 0. The trial was stopped early, after just 1.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

The trial was sponsored by AstraZenecathe marketer of Crestor rosuvastatin. There were no significant differences between the treatment groups with respect to muscle pain, muscle weakness, jupitfr function, or renal function; however, the researchers noted small but statistically significant increases in the rate of physician-reported diabetes and glycated hemoglobin values in the mupiter group, an effect that has also been seen in studies with other statins.

Michel de Lorgeril, et al. The article’s authors critiqued what they saw as flaws in the trial, pointing out that the cardiovascular mortality rate and the case-fatality rate for myocardial infarction were much lower than they expected. They also raised concerns about conflict of interest in the trial design and leadership: They concluded that, “The results of the nemj do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors.


On the role of C-reactive protein, a study employing Mendelian randomizationpublished in the Journal of the American Medical Association suggested that CRP does not play a causal role in cardiovascular nfjm the results may argue against CRP’s use as a marker of cardiovascular disease neejm or for identifying subjects for statin therapy as in JUPITER, and more strongly argue against using CRP as a therapeutic target per se.

From Wikipedia, the free encyclopedia. Results, Controversies, and Implications for Prevention”.


Cardiovascular Quality and Outcomes. Cleve Clin J Med.

Retrieved July 1, Retrieved from ” https: Clinical trials related to cardiology Clinical trials sponsored by AstraZeneca Statins.

Views Read Edit View history. This page was hejm edited on 4 Novemberat By using this site, you agree to the Terms of Use and Privacy Policy.